Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bristol-Myers Squibb Company et al v. Mylan Pharmaceuticals Inc.
Case Number:
1:17-cv-00379
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 18, 2018
Bristol-Myers, Pfizer's Blood Thinner IP Suit Axed Over Venue
A Delaware federal judge tossed a lawsuit filed by Bristol-Myers Squibb Co. and Pfizer Inc. seeking to block Mylan Pharmaceuticals Inc. from making a generic version of their patented blood thinner Eliquis, finding on Thursday that the suit was filed in the wrong venue in light of the U.S. Supreme Court's TC Heartland ruling.
-
September 18, 2017
3 Takeaways From Delaware's TC Heartland Venue Guidance
The District of Delaware's chief judge recently held in two rulings that companies must have permanent ties to the state to face patent suits there following the U.S. Supreme Court's TC Heartland ruling, and his analysis could keep many generic-drug cases in his court. Here's what attorneys can learn from the decisions.
-
September 12, 2017
Del. Chief Judge Sets Post-TC Heartland Venue Guidelines
The District of Delaware’s chief judge said Monday that after a recent U.S. Supreme Court ruling, companies must have a permanent and physical presence in the state to be sued there for patent infringement, so he transferred one case and ordered further discovery in another.